Peptide Therapy 101: The Peptides We Evaluate and Why
Peptide therapy has become one of the most discussed areas in regenerative medicine, metabolic health, sexual wellness, injury recovery, and healthy aging.
Some peptides are established prescription medications supported by substantial human clinical evidence. Others are FDA-approved for one narrowly defined condition but promoted elsewhere for unapproved uses. Several popular peptides remain investigational and have little meaningful human safety or efficacy data.
That distinction matters.
Peptide therapy should not begin with an online list of purported benefits or a predetermined injection protocol. It should begin with a diagnosis, a medical objective, a review of the available evidence, and a clear discussion of what is known and unknown.
At Carroll Total Healthcare, Dr. Brent T. Carroll evaluates peptide therapy within the broader context of family medicine, sports medicine, metabolic health, regenerative medicine, and preventive care. His role is not simply to identify a peptide that matches a symptom. It is to determine whether peptide therapy is medically reasonable, whether a better-established option exists, and whether the potential benefit justifies the risk.
What Is Peptide Therapy?
Peptides are short chains of amino acids. Amino acids are the building blocks used to form proteins, but shorter peptide sequences can also act as biological signals.
Different peptides may interact with receptors involved in:
- Appetite and glucose regulation
- Growth hormone signaling
- Sexual function
- Fertility
- Inflammation
- Tissue communication
- Metabolism
- Body composition
- Skin and connective tissue
- Recovery-related biological pathways
The term peptide therapy refers to the medical use of a peptide-based drug or compounded preparation to influence a particular physiological pathway.
However, peptide therapy is not one uniform treatment category.
Tirzepatide, for example, is an FDA-approved peptide-based medication with large clinical trials supporting specific uses. Retatrutide remains investigational and cannot legally be compounded for patient treatment. BPC-157 is widely promoted online but has extremely limited human evidence and is not FDA-approved.
Putting these substances under the same “peptide” label does not mean they have the same evidence, safety profile, manufacturing standards, or regulatory status.
Why Are Peptides So Popular?
Interest in peptide therapy has increased because peptides can target specific biological pathways and are often marketed as more precise than conventional medications.
Patients commonly ask about peptide therapy for:
- Weight management
- Low energy
- Loss of muscle
- Abdominal fat
- Reduced libido
- Erectile or sexual concerns
- Injury recovery
- Joint and tendon problems
- Sleep
- Skin quality
- Healthy aging
- Reduced exercise recovery
Some of these goals may have a legitimate medical basis. Others are supported primarily by laboratory studies, animal research, anecdotal reports, or commercial claims.
A biological mechanism can be scientifically interesting without proving that a treatment is safe or effective in humans.
How Dr. Carroll Approaches Peptide Therapy
Dr. Carroll’s approach begins by determining what the patient is actually trying to treat.
Fatigue, for example, may be related to sleep apnea, thyroid disease, anemia, diabetes, medication effects, low testosterone, depression, cardiovascular disease, or inadequate sleep.
Difficulty losing weight may involve insulin resistance, menopausal changes, poor sleep, medication effects, eating patterns, reduced muscle mass, thyroid dysfunction, or another metabolic condition.
Persistent tendon pain may reflect tendinopathy, a tear, arthritis, instability, nerve compression, altered mechanics, or an injury requiring surgery.
Peptide therapy should not be used to bypass that diagnostic process.
An appropriate evaluation may include:
- A detailed medical and symptom history
- Review of medications and supplements
- Physical examination
- Laboratory testing when indicated
- Review of imaging or prior records
- Discussion of established treatment options
- Review of peptide-specific evidence and risks
- A monitoring and follow-up plan
The following peptides represent treatments patients may discuss with Dr. Carroll. Their inclusion does not mean that every product is appropriate, FDA-approved, lawfully compoundable, or available for every patient.
Metabolic and Weight-Management Peptides
Tirzepatide
Tirzepatide is one of the most clinically established peptide-based medications used in metabolic medicine.
It activates both glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1, receptors.
Tirzepatide is FDA-approved under different brand names for specific indications:
- Mounjaro for improving glycemic control in adults with type 2 diabetes
- Zepbound for chronic weight management in qualifying adults
- Zepbound for certain adults with obesity and moderate-to-severe obstructive sleep apnea
For appropriate patients, tirzepatide can reduce appetite, improve satiety, support substantial weight loss, and improve several metabolic risk factors.
Peptide therapy with tirzepatide still requires medical supervision. Potential adverse effects include nausea, vomiting, diarrhea, constipation, abdominal discomfort, gallbladder disease, dehydration, pancreatitis concerns, and loss of lean mass during rapid weight reduction.
It is not appropriate for every patient. Medical history, concurrent medications, gastrointestinal symptoms, nutritional intake, body composition, and contraindications must be reviewed.
The FDA has also warned patients and clinicians about quality, dosing, and fraudulent-labeling concerns involving unapproved compounded GLP-1 products. Compounded drugs are not FDA-approved and are not reviewed in advance for safety, effectiveness, or quality.
Retatrutide
Retatrutide is an investigational medication that activates GLP-1, GIP, and glucagon receptors.
Early clinical trials have generated substantial interest because of the weight-loss results observed in research participants. However, retatrutide remains under clinical investigation.
It is not an FDA-approved medication.
More importantly, the FDA states that retatrutide cannot be used in human drug compounding under federal law. It is not a component of an approved drug and has not been established as safe and effective for any condition.
Patients may encounter websites or clinics claiming to sell compounded retatrutide. Online availability does not establish legality, purity, identity, sterility, or safety.
Carroll Total Healthcare does not present investigational retatrutide as an approved peptide therapy option.
Growth Hormone-Releasing Peptides
Several peptides are used or promoted to stimulate the body’s growth hormone signaling rather than administering growth hormone directly.
These products should not be described as general anti-aging treatments. Growth hormone and insulin-like growth factor 1 affect multiple systems and can produce clinically meaningful adverse effects when used inappropriately.
Sermorelin
Sermorelin is a synthetic version of a portion of growth hormone-releasing hormone.
It signals the pituitary gland to release growth hormone. It is often marketed for sleep, recovery, lean body mass, exercise performance, reduced abdominal fat, and healthy aging.
Sermorelin is not currently an FDA-approved drug product. Earlier approved sermorelin products were discontinued, and products marketed today are generally compounded or sold through unapproved channels.
Evidence for broad anti-aging or performance claims is limited.
A responsible peptide therapy evaluation should consider:
- Symptoms and treatment goals
- IGF-1 levels when clinically relevant
- Pituitary function
- Glucose regulation
- Cancer history
- Sleep apnea
- Fluid retention
- Joint symptoms
- Potential medication interactions
Possible adverse effects may include injection-site reactions, headache, flushing, dizziness, fluid retention, tingling, changes in glucose regulation, and excessive growth hormone signaling.
CJC-1295 and Ipamorelin
CJC-1295 and ipamorelin are often combined in peptide therapy programs intended to stimulate growth hormone release through complementary pathways.
CJC-1295 is a growth hormone-releasing hormone analog. Ipamorelin is a growth hormone secretagogue that acts at the ghrelin receptor.
These compounds are frequently promoted for:
- Sleep quality
- Exercise recovery
- Lean mass
- Fat reduction
- Energy
- Healthy aging
- Tissue recovery
These promotional uses are not supported by the type of large, long-term human trials required for an FDA-approved anti-aging or body-composition therapy.
CJC-1295 and ipamorelin are not FDA-approved medications for these purposes.
Potential concerns include changes in glucose regulation, fluid retention, numbness or tingling, headache, joint discomfort, excessive IGF-1 levels, and uncertain long-term effects.
Peptide therapy involving growth hormone pathways should not be prescribed solely because a patient wants to look younger, gain muscle faster, or push hormone levels beyond a normal physiologic range.
Tesamorelin
Tesamorelin is a growth hormone-releasing factor analog and is FDA-approved as EGRIFTA WR for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
That indication is specific.
Tesamorelin is not FDA-approved as a general weight-loss medication, bodybuilding drug, anti-aging treatment, or routine therapy for age-related abdominal fat.
It may increase growth hormone and IGF-1 signaling. Potential risks include glucose intolerance, diabetes, fluid retention, joint discomfort, injection-site reactions, and concerns in patients with active malignancy.
Using tesamorelin outside its approved indication requires a separate medical and legal analysis. The existence of an FDA-approved tesamorelin product does not mean every proposed use is approved or supported by adequate evidence.
Recovery and Regenerative Peptides
BPC-157
BPC-157 is one of the most heavily promoted peptides in regenerative and sports medicine.
Animal and laboratory studies have explored its potential effects on:
- Tendon healing
- Ligament repair
- Gastrointestinal tissue
- Blood vessel formation
- Inflammatory signaling
- Muscle injury
- Wound healing
Human evidence remains extremely limited.
BPC-157 is not FDA-approved for injury recovery, pain, gastrointestinal disease, or any other medical condition. Standardized human dosing and long-term safety have not been established.
The FDA has identified potential safety concerns involving immune reactions, peptide-related impurities, and characterization of the active ingredient.
A patient should therefore not assume that BPC-157 is a proven substitute for physical therapy, diagnostic imaging, appropriate rehabilitation, PRP, surgery, or another evidence-based treatment.
At Carroll Total Healthcare, questions about BPC-157 are addressed within a complete sports medicine or regenerative medicine evaluation rather than through a one-size-fits-all protocol.
KLOW Peptide Blend
KLOW is a commercial name commonly used for a four-peptide blend containing:
- KPV
- GHK-Cu
- BPC-157
- TB-500 or a thymosin beta-4-related fragment
The blend is promoted online for inflammation, connective tissue support, wound healing, skin quality, gut health, and exercise recovery.
KLOW is not a standardized FDA-approved medication. There is no FDA-approved KLOW product, established formulation, approved indication, validated dosing protocol, or robust human clinical evidence demonstrating that the four-component combination is safe and effective.
Evidence involving one ingredient should not be treated as proof that a multi-peptide blend produces the same effect. Combining multiple investigational substances also makes it more difficult to determine which component caused a benefit, adverse effect, or interaction.
KLOW should therefore be presented as an investigational blend, not as a proven full-body repair treatment.
MOTS-c
MOTS-c is a mitochondrial-derived peptide. It is produced from genetic material within mitochondria and has attracted scientific interest because of its potential relationship to cellular metabolism, glucose use, exercise response, and age-related metabolic changes.
Most of the excitement surrounding MOTS-c comes from laboratory and animal research.
MOTS-c is not FDA-approved for fatigue, weight loss, insulin resistance, exercise enhancement, longevity, or another therapeutic use.
The FDA has identified potential concerns involving immune reactions, peptide impurities, and difficulty characterizing the active ingredient in compounded MOTS-c products.
Its role in human peptide therapy remains investigational. It should not be marketed as a proven way to improve mitochondrial function or extend lifespan.
Sexual Health and Reproductive Peptides
PT-141 and Bremelanotide
PT-141 is another name commonly used for bremelanotide.
Bremelanotide is FDA-approved under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women.
It is not approved for every form of low libido, for postmenopausal sexual dysfunction, or as a general sexual-performance drug for men.
Bremelanotide acts through melanocortin receptors rather than directly increasing blood flow in the same manner as common erectile dysfunction medications.
Potential adverse effects include:
- Nausea
- Flushing
- Headache
- Injection-site reactions
- Temporary increases in blood pressure
- Reductions in heart rate
- Darkening of the skin or gums with repeated exposure
It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.
Peptide therapy involving PT-141 requires a complete sexual and medical history. Low desire can result from hormonal changes, medication effects, relationship factors, pain, depression, menopause, vascular disease, or other conditions.
Human Chorionic Gonadotropin
Human chorionic gonadotropin, or hCG, is a glycoprotein hormone that is often grouped with peptides because of its amino-acid structure and receptor-based biological activity.
Prescription hCG has FDA-approved uses involving selected fertility and hormonal conditions.
In men, hCG can stimulate the testicles to produce testosterone and support sperm production under appropriate medical circumstances. It may be considered in selected patients with secondary hypogonadism or fertility goals.
It is not FDA-approved for weight loss.
The FDA specifically warns that hCG has not been approved for obesity treatment and that products promoting hCG diets often pair the hormone with dangerously restrictive calorie intake.
Men considering hCG require appropriate hormonal testing and evaluation of:
- Fertility goals
- Testosterone levels
- Luteinizing hormone
- Follicle-stimulating hormone
- Testicular function
- Estradiol
- Medication use
- Pituitary health
Potential adverse effects can include breast tenderness, increased estradiol, fluid retention, mood changes, acne, injection-site reactions, and ovarian hyperstimulation in women receiving fertility treatment.
Are All Peptides FDA-Approved?
No.
The peptide therapy market contains several distinct categories:
FDA-approved peptide medications
These medications have undergone regulatory review for defined indications. Examples include tirzepatide, tesamorelin, bremelanotide, and prescription hCG.
Approval applies to the specific drug, formulation, population, dose, and indication described in its labeling.
Off-label use of approved medications
A physician may sometimes prescribe an approved medication for a use that does not appear in its FDA-approved labeling.
Off-label use is not automatically improper, but it should be supported by medical rationale, appropriate evidence, informed consent, and professional judgment.
Compounded peptide preparations
Compounded medications may serve a legitimate need when an FDA-approved product cannot meet an individual patient’s medical requirements.
Compounded drugs are not FDA-approved. The FDA does not verify their safety, effectiveness, quality, strength, or purity before they are dispensed.
Poor compounding practices can result in contamination, incorrect potency, or other serious quality problems.
Investigational peptides
Investigational peptides have not been approved for routine patient treatment. Some remain within formal clinical development. Others are primarily supported by preclinical studies and online marketing.
“Research use only” products should not be purchased and self-injected.
What Should Patients Expect From Peptide Therapy?
The process depends on the treatment being considered, but a responsible peptide therapy program may include:
Initial evaluation
Dr. Carroll reviews the patient’s symptoms, diagnoses, medications, medical risks, goals, and prior treatment.
Baseline testing
Laboratory testing may assess metabolic health, hormone function, organ function, blood counts, glucose regulation, and other relevant markers.
Treatment selection
Dr. Carroll determines whether peptide therapy is medically justified and compares it with FDA-approved medications, lifestyle intervention, physical therapy, regenerative procedures, hormone treatment, or other options.
Informed consent
Patients should understand whether a treatment is FDA-approved, off-label, compounded, or investigational.
Monitoring
Follow-up may include symptom review, physical measurements, laboratory testing, adverse-effect monitoring, and decisions about whether treatment should continue.
Adjustment or discontinuation
Peptide therapy should be changed or stopped when it is ineffective, poorly tolerated, medically unnecessary, or producing unacceptable risk.
Who May Not Be a Candidate?
The answer depends on the individual peptide.
Peptide therapy may be inappropriate or require additional caution for patients with:
- Pregnancy or breastfeeding
- Active or recent cancer
- Uncontrolled cardiovascular disease
- Significant liver or kidney disease
- Severe gastrointestinal disease
- Endocrine tumors
- Untreated sleep apnea
- Uncontrolled diabetes
- Significant psychiatric instability
- Allergy to product ingredients
- A history of pancreatitis or gallbladder disease
- Unrealistic expectations
- Use of conflicting medications
This list is not exhaustive. Each peptide has its own contraindications and monitoring requirements.
Why Physician Oversight Matters
Online peptide sellers frequently encourage patients to choose a product based on a symptom, calculate a dose themselves, reconstitute a powder at home, and inject it without meaningful medical supervision.
That is not responsible peptide therapy.
Products purchased through unverified websites may be mislabeled, underdosed, overdosed, contaminated, nonsterile, or entirely different from what the label claims.
Dr. Carroll is a board-certified family medicine and sports medicine physician with more than two decades of clinical experience. His training allows him to evaluate peptide-related questions within the complete medical picture rather than viewing every concern as a peptide deficiency.
The most important clinical decision may be selecting a peptide. It may also be determining that a peptide is not the appropriate treatment.
The Bottom Line on Peptide Therapy
Peptide therapy is neither a medical miracle nor an inherently illegitimate field.
Some peptide medications are FDA-approved, clinically validated, and highly useful for appropriate patients. Others are prescribed off-label under medical supervision. Several popular wellness peptides remain investigational, with limited human evidence and unresolved safety or regulatory concerns.
The quality of peptide therapy depends on:
- The accuracy of the diagnosis
- The evidence supporting the treatment
- The product’s regulatory status
- Pharmacy and manufacturing quality
- Appropriate patient selection
- Honest informed consent
- Conservative dosing
- Medical monitoring
- Willingness to stop ineffective treatment
Patients in Cumming, Forsyth County, Vickery, Windermere, Creekstone Estates, Polo Golf and Country Club, The Manor, and surrounding North Georgia communities can schedule a physician-led peptide therapy evaluation at Carroll Total Healthcare.
The objective is not to place every patient on the newest peptide.
It is to determine which treatment offers a reasonable balance of evidence, safety, and potential benefit for that individual patient.
Frequently Asked Questions About Peptide Therapy
What is peptide therapy used for?
Depending on the specific medication, peptide therapy may be used for weight management, diabetes, selected hormonal conditions, fertility, HIV-associated lipodystrophy, sexual desire disorders, or other defined medical indications. Many popular wellness uses remain off-label or investigational.
Is peptide therapy FDA-approved?
Some peptide medications are FDA-approved. Others are compounded, prescribed off-label, or investigational. Patients should ask about the status of the exact product being recommended.
Is peptide therapy the same as hormone therapy?
No. Some peptides stimulate hormonal pathways, but peptide therapy and hormone replacement are not interchangeable terms.
Are peptides safe?
Safety depends on the specific peptide, dose, formulation, patient, indication, manufacturing quality, and monitoring. It is not accurate to describe peptides as universally safe because they are based on amino acids.
Can peptide therapy help with weight loss?
FDA-approved tirzepatide can support weight management in qualifying patients. Retatrutide remains investigational and cannot lawfully be compounded. Other peptides should not be presented as proven weight-loss treatments without adequate evidence.
Can peptides improve injury recovery?
Certain investigational peptides are being studied for pathways related to tissue repair, but evidence for products such as BPC-157 and KLOW remains limited. An accurate sports medicine diagnosis should come before any recovery-focused treatment.
Can peptides improve libido?
Bremelanotide is FDA-approved for a specific form of low sexual desire in certain premenopausal women. Sexual symptoms require evaluation because hormones, medications, vascular health, menopause, relationships, mental health, and other factors may contribute.
Where can patients in Forsyth County discuss peptide therapy?
Carroll Total Healthcare in Cumming, Georgia, provides physician-led consultations for metabolic health, hormone concerns, sports medicine, regenerative medicine, weight management, and appropriate peptide-based treatments.
Medical Disclaimer: This article is provided for general educational purposes and does not constitute individualized medical advice. Availability of a treatment does not establish that it is appropriate for a particular patient. Some therapies discussed are FDA-approved only for limited indications, while others are compounded, off-label, or investigational. Retatrutide is not FDA-approved and cannot lawfully be compounded for human use under current federal law.